Press Releases Oxford Biomedica plc

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 05:00:13 2026-04-13 am EDT			5-day change	1st Jan Change
565.00 ^GBX	-0.18%		+2.73%	-8.43%

04:05am	Oxford Biomedica PLC Launches Fast-Track Offering For AAV And Lentiviral Vector Platforms	CI
Mar. 30	WINNERS & LOSERS: Miners climb; Close Brothers down before FCA verdict	AN

Press Releases

Mar. 30	OXB recognised as Most Innovative CDMO at 2026 CDMO Leadership Awards	AQ
Mar. 30	Oxford Biomedica : 2026 Notice of Annual General Meeting 30 March 2026	PU
Mar. 27	OXB recognised as ‘Most Innovative CDMO (Cell & Gene)’ at 2026 CDMO Leadership Awards	AQ
Mar. 26	Preliminary results for the year ended 31 December 2025	AQ
Mar. 26	Oxford Biomedica : Preliminary Results for the year ended 31 December 2025 26 March 2026	PU
Mar. 18	OXB enters into licensing agreement with Viral Vector Manufacturing Facility (VVMF), providing access to its AAV and LV viral vector platforms	AQ
Feb. 24	Full year Trading Update and Notice of Results	AQ
Feb. 23	Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc	EQ
Feb. 16	Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc	EQ
Feb. 12	Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc	EQ
Jan. 15	Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc	EQ
25-10-29	OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category	AQ
25-10-27	OXB to participate in upcoming investor conferences and events	AQ
25-10-07	OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina	AQ
25-09-23	Oxford Biomedica : OXB Interim Results Presentation 2025 23 September 2025	PU
25-06-12	OXB - AGM Update	AQ
25-06-11	AGM Update	AQ
25-06-03	OXB Highlights the Launch of its Innovation and Technology Excellence Board	AQ
25-05-09	OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	AQ
25-04-09	Oxford Biomedica : Preliminary Results for the year ended 31 December 2024 9th April 2025	PU
25-03-28	ViroCell Biologics Appoints Viral Vector Expert as Special Advisor	AQ
25-03-21	OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category	AQ
25-02-26	OXB to present at the Leerink Partners Global Healthcare Conference	AQ
25-02-20	OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis	AQ
25-02-18	BEST OF THE BROKERS	AQ